Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases.The transaction values Abpro at $725 million and will help advance Abpro’s drug pipeline to clinical trials.WOBURN, Mass. & NEW YORK (BUSINESS.
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp II streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group’s trust account be.
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics.
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi.